Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX

Eagle Health Investments LP acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $5,005,000. Protagonist Therapeutics comprises approximately 1.1% of Eagle Health Investments LP’s investment portfolio, making the stock its 21st biggest position.

Several other institutional investors have also recently modified their holdings of the company. PSP Research LLC bought a new position in shares of Protagonist Therapeutics during the 4th quarter valued at about $535,000. Covestor Ltd increased its position in shares of Protagonist Therapeutics by 45.2% during the 4th quarter. Covestor Ltd now owns 1,437 shares of the company’s stock valued at $125,000 after purchasing an additional 447 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Protagonist Therapeutics by 8.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock valued at $258,000 after purchasing an additional 221 shares during the last quarter. Handelsbanken Fonder AB increased its position in shares of Protagonist Therapeutics by 5.3% during the 4th quarter. Handelsbanken Fonder AB now owns 19,900 shares of the company’s stock valued at $1,738,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Profund Advisors LLC increased its position in shares of Protagonist Therapeutics by 40.8% during the 4th quarter. Profund Advisors LLC now owns 25,574 shares of the company’s stock valued at $2,234,000 after purchasing an additional 7,417 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $104.79, for a total transaction of $1,571,850.00. Following the transaction, the insider directly owned 84,115 shares in the company, valued at $8,814,410.85. This trade represents a 15.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Asif Ali sold 24,765 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $104.24, for a total value of $2,581,503.60. Following the transaction, the chief financial officer owned 60,753 shares in the company, valued at approximately $6,332,892.72. The trade was a 28.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 254,345 shares of company stock worth $25,810,506 over the last quarter. Company insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Price Performance

PTGX opened at $100.88 on Thursday. The stock’s 50 day simple moving average is $101.13 and its 200 day simple moving average is $91.05. Protagonist Therapeutics, Inc. has a 1 year low of $45.05 and a 1 year high of $107.84. The firm has a market cap of $6.49 billion, a price-to-earnings ratio of -55.73 and a beta of 1.89.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. As a group, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.55 EPS for the current year.

Wall Street Analyst Weigh In

PTGX has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. TD Cowen increased their price objective on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Citigroup reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Wolfe Research began coverage on Protagonist Therapeutics in a research report on Thursday. They set an “outperform” rating on the stock. Finally, Wall Street Zen upgraded Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $113.69.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.